Calidi Biotherapeutics (CLDI) director Schoeneck received 28,207 shares
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
James A Schoeneck (director at Calidi Biotherapeutics Inc., CLDI) reported that they received 28,207 shares on Mar 29, 2024. After these transactions the filing shows 992,094 shares held directly.
- Reporting person
- Schoeneck James A
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Mar 29, 2024 | Grant or award (A) | Common Stock1 | +28,207 | - | - | 992,094 direct |
Holdings before and after
- Common Stock: 963,887 to 992,094 direct
Footnotes from the filing
- 1. Represents a grant of restricted stock units ( RSUs ) on March 29, 2024 (the Grant Date ), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's first fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Schoeneck report in this CLDI Form 4?
James A Schoeneck (director at Calidi Biotherapeutics Inc., CLDI) reported that they received 28,207 shares on Mar 29, 2024. After these transactions the filing shows 992,094 shares held directly.
How many CLDI shares does Schoeneck hold after this filing?
The filing shows 992,094 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for CLDI
Earlier insider filings at CLDI
- Jul 3, 2024Director Stewart Alan R. was granted 25,995 shares, increasing direct ownership by 48% to 80,650 units (SEC Form 4)
- Jun 21, 2024SEC Form 4 filed by Chief Financial Officer Jackson Andrew C.
- Jun 21, 2024SEC Form 4 filed by CEO and Chairman of the Board Camaisa Allan
- Jun 21, 2024SEC Form 4 filed by Chief Admin. and Legal Officer Campbell Wendy Pizarro
- Jun 21, 2024SEC Form 4 filed by Interim Chief Medical Officer Minev Boris Radoslavov
Quantisnow market dataAMEX
CLDI
Calidi Biotherapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2021
Get push alerts for CLDI
Full CLDI profile on Quantisnow Follow CLDI and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time